5 hrs ago | WOIO
Istodax Approved for Cutaneous T-Cell Lymphoma
The Gloucester Pharmaceuticals drug Istodax has been approved by the U.S. Food and Drug Administration to treat cutaneous T-cell lymphoma in people who have tried at least one prior systemic therapy, the drug's manufacturer said in a news release.
17 hrs ago | MediLexicon
Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia
Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Clinical Trials / Drug Trials Sunesis Pharmaceuticals, Inc.
Researchers Find New Way to Attack Inflammation in Graves' Eye Disease
A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms - and improved vision - following treatment with the drug rituximab.
Gloucester cancer drug wins FDA approval
The U.S. Food and Drug Administration has approved a lymphoma drug developed by privately held biotechnology firm Gloucester Pharmaceuticals .
New data published today in the journal, Cancer , reveals that three quarters of patients with indolent B-cell non-Hodgkin's lymphoma , responded to treatment with Bendamustine following a single-arm, multicentre study.
Final Radiation Dose Expected For Minn. Teen
The end of cancer treatment and court hearings could be in sight for Sleepy Eye teen Daniel Hauser.
Stem Cell Therapy International, Inc. And Histostem Korea Announce...
Main Category: Stem Cell Research Also Included In: Lymphoma / Leukemia / Myeloma Article Date: 06 Nov 2009 Stem Cell Therapy International Inc.
Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer
A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in the International Journal of Cancer .
Cancer drug blow for champion athlete
A pillar of Hastings' athletic community has been denied funding for a trial cancer drug which could save his life.
Gloria Full lives in a comfortable home in Ahwatukee Foothills. It is filled with cards, flowers and pictures of her family.
StemEx(R) Noted As A Reliable Investigational Product Of An Expanded...
Main Category: Stem Cell Research Also Included In: Blood / Hematology ; Conferences Article Date: 03 Nov 2009 - 1:00 PST At a symposium today in Herzliya entitled Umbilical Cord Blood: An Alternative for Bone Marrow Transplantation in Adults, bone marrow transplantation experts Professor Patrick Stiff and Professor Guillermo Sanz addressed ...
NOXXON Announces Initiation of First-in-Human Clinical Trial with...
NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer NOX-A12. NOX-A12 is NOXXON's second drug candidate entering the clinical stage of ...
Immune Therapy Can Protect Against Or Treat Later Lymphoma
Specially developed immune system cells that target the common Epstein-Barr virus can protect immune-suppressed bone marrow transplant recipients against lymph system disease and cancers that arise from the viral infection, said a group of researchers led by those from Baylor College of Medicine, The Methodist Hospital and Texas Childrena s ...
Cancer Treatment's Effect on Getting Pregnant
Cancer is a word you never want a doctor to say to you. When you're older, it's traumatic enough, but when you're young and still thinking about your whole life and future family, it is devastating.
Cellphone radiation, clock radios can act as catalysts for cancer
Cellphone radiation, clock radios can act as catalysts for cancer An Australian brain cancer surgeon has called upon people to use mobile phones and clock radios with caution as, according to him, they are catalysts for cancer.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue.
Another 'BiTE' as Micromet Inks Potential 320M Sanofi Alliance
With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound.
6 Cancer Symptoms Women Can't Ignore
Few showers. Low 52. FRIDAY: Mostly cloudy, breezy & mild. Few showers, mainly northwest of Columbus.
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways
E-mail: weili_zhao_sih@yahoo.com Received 28 June 2009; Revised 22 August 2009; Accepted 28 August 2009; Published online 29 October 2009.
The Risk of Lymphoma Development in Autoimmune Diseases
Background The risk of development of non-Hodgkin lymphoma in autoimmune patients has been investigated in several cohort studies.
Also on Topix